Another technique incorporating a maturation step analogous to a different but commonly used technique in GBM DC vaccine clinical trials32–35 (M2) efficiently generated CD83+ mature DCs from healthy volunteer monocytes (84.5% ± 9.8%) but not from GBM patients (70.9% ± 19.3%; P < .05). This evidence concerns the gene CD83 and glioblastoma.